AGTR1 and neoplasm: Still more preclinical evaluations are needed to determine the real effectiveness of this new and emerging class of angiotensin peptides for tumor detection; however, the outcome of this study can be beneficial for the designing of more efficacious peptide-based agents for the efficient targeting of AT1 receptor-positive tumors.